▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4215 by analyst upside · 2026-09-27
TWST
Twist Bioscience Corporation
Healthcare · Market Cap $12B · P/E 0x
ANALYST PRICE TARGET
-40.1%
implied upside to consensus target
Current Price $182.83
Consensus Target $109.58
Bull Target $160.0
Bear Target $36.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
3
Sell
1
52-Week Low $23.3
52-Week High $186.2
YTD Return +464.5%
FUNDAMENTALS
Market Cap $12B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.23
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $432M
Profit Margin -31.7%
52-WEEK RANGE
52-Week Low $23.3
52-Week High $186.2
Current Price $182.83
Bear Target $36.0
Bull Target $160.0
● Now $182.83 ● Target $109.58
TRADING DATA
Avg Volume 1.7M
YTD Return +464.5%
Analyst Count 12
Consensus Buy
Upside to Target -40.1%
Last Updated 2026-09-27

ANALYST SUMMARY

Twist Bioscience Corporation (TWST) is currently trading at $182.83 with a Wall Street consensus price target of $109.58, which is 40.1% below the current price over the next 12 months. 12 analysts currently cover TWST, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $160.0, while the most cautious has a target of $36.0.

TWST operates in the Healthcare sector with a market capitalisation of $12B. The stock is up 464.5% year-to-date and is currently trading near the upper end of its 52-week range of $23.3 – $186.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CAI -12.0%
Caris Life Sciences, Inc.
$9B · P/E 3.3x · Buy
UHS +8.7%
Universal Health Services, Inc.
$11B · P/E 7.3x · Hold
FMS +11.7%
Fresenius Medical Care AG
$12B · P/E 12.0x · Hold
SOLV +4.9%
Solventum Corporation
$15B · P/E 10.9x · Hold
EXEL -7.7%
Exelixis, Inc.
$14B · P/E 18.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for TWST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BWS Financial - Reiterated
Sell → Sell 2026-09-18 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-17 29% win rate (7 calls)
BWS Financial ● Initiated
Sell 2026-09-09 Building track record
UBS ● Initiated
Neutral 2026-09-09 33% win rate (6 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-05 14% win rate (7 calls)
Baird - Reiterated
Outperform → Outperform 2026-08-04 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-07-14 Building track record
Evercore ISI Group ↓ Downgrade
Outperform → In-Line 2026-07-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
20/30
Consensus clarity
16/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →